Biomarkers UK 2022 – May 3-4
Presentation
Erin Newburn, PhD
Sr. Director, Field Applications Scientist
Personalis, Inc.
Tuesday, May 3 | 2:55 PM BST
Personalis NeXT Platform
Enabling precision oncology with comprehensive tumor profiling solutions for tissue and liquid biopsy
- Combining sensitive DNA and RNA sequencing with advanced analytics, ImmunoID NeXTTM provides a multidimensional view of the tumor and microenvironment
- A melanoma cohort case study demonstrates how a composite biomarker strengthens the association with immunotherapy response
- NeXT PersonalTM, an ultrasensitive, tumor-informed liquid biopsy assay, designed to detect molecular residual disease will be highlighted
Connect with us at Biomarkers UK 2022
